Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “eligible participants will be randomized to 1 of 2 or more treatment arms, depending on the number of CNT201 doses selected for administration in Step 2”In the company’s words, NCT07640425 on ClinicalTrials.gov
- Tested for
- Dupuytren Contracture, Dupuytren Disease of Finger
- Main trialPhase 1/2
- “This trial is a multicenter, Phase 1/2, study to assess the safety, tolerability, efficacy, PK, and immunogenicity of CNT201 in adult participants with DC (Dupuytren's Contracture).”In the company’s words, NCT07640425 on ClinicalTrials.gov
Coming up1
- 1 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 1 Jul 2027 | Safety and Efficacy Study of Collagenase CNT201 Injection for Treatment of Dupuytren's Contracture |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026